AI-Generated Summary

The Trump administration announced a 100% tariff on branded or patented pharmaceutical products starting October 2025, aiming to incentivize US-based manufacturing. While India's generic exports are currently exempt, the policy sparked sharp declines in Indian pharma stocks due to market uncertainty. This move signals a significant shift in global pharmaceutical supply chains and trade policy, impacting market access and manufacturing strategies.

In a nutshell

This tariff represents a significant escalation in US efforts to onshore pharmaceutical manufacturing, potentially reshaping global supply chains and investment strategies for branded drugmakers. While generics are currently exempt, the broader policy direction introduces considerable uncertainty for international pharmaceutical trade and market stability.

Source: Hindustan Times